-
The first in China!
Time of Update: 2021-06-20
On June 7, the new drug clinical trial application (IND) of the antibody-conjugated drug MRG004A that targets tissue factor (TF) submitted by Shanghai Miac, a wholly-owned subsidiary of Lepu Bio, was accepted by CDE .
-
Hengrui Medicine's Carrelizumab was approved for the world's first first-line nasopharyngeal cancer indication
Time of Update: 2021-06-20
Recently, the PD-1 inhibitor Carrelizumab (Erica®) independently developed by Hengrui Medicine has officially obtained the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA), approving Carrelizumab Monoclonal antibody combined with cisplatin and gemcitabine is used for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
-
How amazing is the 5-year survival rate of brain tumors that is 6 times that of tumor electric field therapy?
Time of Update: 2021-06-20
As a physical therapy, TTF has less side effects on the human body compared to traditional tumor treatment methods such as radiotherapy and chemotherapy .
-
The State Food and Drug Administration approves the marketing of Donafinil tosylate tablets
Time of Update: 2021-06-20
On June 9, the official website of the State Food and Drug Administration announced that the State Food and Drug Administration recently passed the priority review and approval procedure to approve the Class 1 innovative drug Donafenib Tosylate (trade name:) declared by Suzhou Zejing Biopharmaceutical Co.
-
Increasing investment in Suzhou BeiGene steadily accelerates global industrialization layout
Time of Update: 2021-06-20
Recently, the company independent research and development of new cancer drugs third paragraph Parkway Chak ® formally NMPA conditional marketing approval, and in just three days to achieve a seamless transition from the industrial base Suzhou shipped and delivered in the hands of patients, successfully Sent to 30 provinces (autonomous regions and municipalities) across the country .
-
The latest clinical application of Eltanexor in the treatment of MDS refractory to demethylation drugs...
Time of Update: 2021-06-20
In the 10 mg dose group (n=5), all patients had clinical benefit, 3 patients (60%) achieved complete bone marrow remission, and 2 patients (40%) had stable disease .
In the 20 mg dose group (n=10), 4 cases (40%) achieved complete bone marrow remission, and 3 cases (30%) had stable disease .
-
The incidence of malignant tumors in children and adolescents has increased. How to protect the fertility of adolescents?
Time of Update: 2021-06-17
In 2018, ASCO updated the guidelines; in 2014, the Chinese Medical Association Gynecological Oncology Branch formulated A "Guidelines for Clinical Diagnosis and Treatment of Gynecological Malignant Tumors with Preserving Fertility Function", the "Expert Consensus on Fertility Protection and Preservation of Chinese Female Cancer Patients" was released in 2020 .
-
[Nature] Cancer "blackout" makes it possible to prevent tumor metastasis
Time of Update: 2021-06-17
Researchers isolated subgroups of aggressive cancer cells with high ATP levels and confirmed that the FDA-approved Bedaquiline drug targets the γ subunit of ATP synthase (ATP5F1C) to inhibit the production and metastasis of mitochondrial ATP in the body .
-
ASCO 2021 Prof. Zhimin Shao interprets the data of monarchE Chinese population: Abesiride combined with endocrine therapy for early breast cancer reduces the risk of recurrence by 34%
Time of Update: 2021-06-17
MonarchE research Chinese population IDFS reporter: In the treatment of early breast cancer, the safety profile of the drug is very important for patients to adhere to the treatment .
-
Efficacy of ixazomib maintenance therapy in high-risk MM patients after 2021 ASCO AlloHCT
Time of Update: 2021-06-17
A phase II study (NCT02440464) evaluated the efficacy of alloHCT and subsequent maintenance therapy with ixazomib in high-risk MM patients receiving a combination of low-dose fludarabine, malphalan, and bortezomib .
-
Courier improves the safety and efficacy of ADC, and Xinrui receives US$47 million in assistance
Time of Update: 2021-06-17
The company's drug development pipeline improves the safety and efficacy of ADCs by combining prodrug payloads that are only activated near the tumor with stable coupling technology .
com/2021/06/iksuda-therapeutics-closes-47-million-financing-round/ Note: This article aims to introduce The progress of medical and health research is not a treatment recommendation .
-
"ALL Hard"-K drug strong "ALL-IN" digestive tract tumors
Time of Update: 2021-06-17
Persevering in the dark night, "liver cancer" KEYNOTE-240 KEYNOTE-240 announced this year’s ASCO conference announced the K drug second-line treatment of unresectable advanced hepatocellular carcinoma treated with sorafenib, a phase III clinical study of KEYNOTE-240 with a median follow-up of 40 months Data analysis results [10] showed that the median OS of the K drug group was 13.
-
2021 ASCO Kidney Cancer: Researchers announce the results of the longest follow-up time for immunotherapy!
Time of Update: 2021-06-17
In the first interim analysis, compared with sunitinib, pembrolizumab + axitinib can significantly improve the overall survival (OS) and progression-free of patients with newly diagnosed advanced clear cell renal cell carcinoma (ccRCC) Survival period (PFS) and objective response rate (ORR) .
-
2021 EHA Big Coffee Talks Professor Fu Weijun: First Look at the Progress of MM&AL Immunotherapy
Time of Update: 2021-06-17
The interim analysis of the second part of CASSIOPEIA shows that among NDMM patients who are suitable for transplantation, Compared with the observation group, the PFS of DARA maintenance treatment was significantly prolonged, and the depth of remission and the negative rate of MRD were significantly increased, and it was safe and tolerable .
-
China's first antibody-conjugated drug (ADC) was approved for the treatment of gastric cancer
Time of Update: 2021-06-17
On June 9, 2021, the National Food and Drug Administration (NMPA) of China announced that it has approved the listing of Rongchang Bioinjection Vedicuzumab (trade name: Aidexi) with conditions through the priority review and approval procedure, which is suitable for at least acceptance Treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) with HER2 overexpression that has undergone two systemic chemotherapy .
-
NMPA News Vidicuzumab and Donafinil Approved for Listing
Time of Update: 2021-06-17
On June 9th, the National Medical Products Administration (NMPA) issued an announcement to pass the priority review and approval procedure with conditional approval of China’s self-developed innovative antibody-conjugated drug (ADC) for injection vedicitumumab, which is suitable for at least Treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received two kinds of systemic chemotherapy .
-
[New research] Deciphering the influencing factors of "Pink Killer"
Time of Update: 2021-06-17
Now, new research by scientists at Wake Forest School of Medicine shows that diets that include fish oil supplements can not only change the breast microbiome, but also breast cancer .
-
Pulmonary Mucormycosis Secondary to Diabetes│Identify the Disease by Shadow
Time of Update: 2021-06-17
Imaging examination After admission, a chest CT scan showed that the right lung had a wide central non-enhanced consolidation area, right pleural effusion, and ground-glass shadows around the left pulmonary blood vessels .
-
Roche's new generation of anti-CD20 monoclonal antibody Jialuohua® approved in China
Time of Update: 2021-06-17
Although the exploration of treatment is advancing all the way, the results have not been satisfactory; the GALLIUM study is the first clinical exploration to achieve the first-line treatment of newly diagnosed follicular lymphoma patients to significantly reduce the risk of disease recurrence and death .
-
2021EHA Big Coffee Comment on Professor Li Juan: Frontier and Hot Spots of Newly Diagnosed Multiple Myeloma
Time of Update: 2021-06-17
[Oral180] CASSIOPEIA study: Compared with the observation group, patients who are suitable for transplantation of NDMM after induction/consolidation therapy have a higher MRD-rate of maintenance therapy with daratumomab, and the PFS is longer.
